CSHP Ontario Branch

November 2017

Point counterpoint: Should digoxin continue to be used for atrial fibrillation?

October 2017

Managing diabetic emergencies – ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS) and hypoglycemia. Are we using evidence-based approaches?

September 2017

Medical marijuana – what is the evidence?
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

August 2017

Idarucizumab for dabigatran reversal(REVERSE-AD trial) Part 2 – Full cohort analysis

July 2017

Tackling one piece of the opioid crisis: Opioid initiation in the ER
Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use.

June 2017

Can PPI and H2 blocker stewardship reduce the risk of clostridium difficile infections?
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.
Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults.

May 2017

Are we underdosing VTE prophylaxis in our obese patients?
Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.

April 2017

Teachable moments:
1) How to clarify a penicillin allergy
2) how to help patients sleep better in the hospital

March 2017

Incretin-based antihyperglycemics and acute pancreatitis: is there a link?
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

February 2017

Med Safety Blast – Health Product InfoWatch November and December 2016 issues

January 2017

Use of potentially inappropriate medications in alternate level of care (ALC) inpatients and a practical review of Beers Criteria
Application of the Beers Criteria to Alternate Level of Care Patients in Hospital Inpatient Units

November:

Knowledge Mobilization of Deprescribing Guidelines: A Story of Whiteboard Videos, Social Media, & More! 
(Background article)

October:

Biosimilars, switch to 'em or ditch 'em? A critical appraisal of the clinical efficacy and safety of biosimilar versus originator insulins

August:

The Vancomycin Voyage: Unraveling Knee Magic and Surgical Marvels!

July:

Critically Appraising a Systematic Review/Meta-Analysis from a Clinician’s Viewpoint - Part 2

CEBM at University of Oxford (attached) AMSTAR  AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both | The BMJ

CASP CASP Checklist (casp-uk.net)

June:

Understanding the Anatomy of a Systematic Review/Meta-Analysis for Critical Appraisal from a Clinician’s Viewpoint

Backgrounder articles: CEBM at University of Oxford (will be provided to registrants) AMSTAR

CASP:CASP Checklist (casp-uk.net)

May:

Safer Opioid Supply – An Emerging Opportunity to Support Harm Reduction in Canada

April:

A Glance at Health Technology Assessment (HTA) at CADTH

March

Fact or CAP: Can we use a shorter course of antimicrobial therapy for inpatient paediatric Community Acquired Pneumonia (CAP)?

February

Demystifying specific gravity in gravimetric sterile compounding - an illuminating study of density variations

January

The Emergence of Real World Evidence (RWE) - Future Directions in Caring for Patients and Why it Should Matter to Pharmacists

November:

SGLT2 Inhibitors DELIVER again - the Evidence in Heart Failure with Preserved Ejection Fraction 

October:

The story of potassium binders and chronic kidney disease 

September:

Strong Enough to Change the Tide? A Critical Appraisal of the Efficacy and Safety of 2.0mg Weekly Semaglutide (SUSTAIN FORTE)

August:

Non-Inferiority Complex? A Critical Appraisal Tutorial of Non-Inferiority Trial Design 

July:

 Balancing the Risks and Benefits of Antimicrobial Prophylaxis after Orthopedic Surgery: A Critical Appraisal of Current Literature

May:

 Is the "syringe pull-back" method pulling us away from compounding best practices? An illuminating study of chemotherapy compounding at 5 U.S. hospitals 

April:

 Pimavanserin for Dementia-related Psychosis: Too good to be true?

February

 Remdesivir in the Outpatient Setting for COVID-19 | Where Does This PINETREE Fit in the Forest of Therapeutics

November:

Integrating the PEN-FAST Allergy Assessment Tool into practice

October:

Prescription Modification by Pharmacists in a Hospital Setting: Are Ontario Pharmacists Ready? A Review of a Recent Provincial Survey and its Practice Implications

September:

Knowledge Translation for the Busy Clinician | Using a Review on Alcohol and Antibiotic Interactions as a Case Study 

August:

Opioid agonist therapy – what mu need to know

July:

Colchicine the Chameleon: A Critical Appraisal of its Utility in Secondary Prevention of Coronary Artery Disease

June:

A Clot Conundrum: A Pharmacist Approach to Vaccine-Induced Thrombotic Thrombocytopenia (VITT) 

April:

SGLT-2 Inhibitors - New indications and Diabetic Ketoacidosis 

March:

Bacterial co-infection and secondary infection in patients with COVID-19

February:

Efficacy and safety of the mRNA-1273 SARS-CoV-2 (Moderna) Vaccine

November 2020

Gram Negative Bacteremia: A Review of the Evidence Surrounding Duration and Route of Therapy

October 2020

What’s the best prescription for pain medication at discharge after elective adult surgery and as hospital pharmacists, what do we say when we talk with patients about opioids?

September 2020

Perioperative management of anti-rheumatic immunosuppressive therapy: Why, When and How?

August 2020

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

July 2020

Development and Validation of a Penicillin Allergy Clinical Decision Rule

February 2020

del Rio C, Malani PN. 2019 Novel Coronavirus—Important Information for Clinicians. JAMA. Published online February 05, 2020. doi:10.1001/jama.2020.1490  

Li, Qun, et al. "Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia." New England Journal of Medicine (2020).

Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. Published online February 07, 2020. doi:10.1001/jama.2020.1585

November 2019

Primary article: Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12.

Backgrounder article: Diagnosis and Management of the Antiphospholipid Syndrome.
N Engl J Med. 2018 May 24;378(21):2010-2021. doi: 10.1056/NEJMra1705454.

October 2019

2019 Annals of Oncology 30:897-907 

September 2019

Primary article: Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics
Backgrounder article: Should prolonged infusion of ß-lactams become standard of practice?

August 2019

A Painful Medication Reconciliation Mishap
Diagnosis and Pharmacotherapy of Alcohol-Use Disorder: A Review

May 2019

SLGT2 inhibitors – Are they the new class in heart failure?

• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes 
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes 
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
• Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. 

April 2019

American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults – A Review of the Updates and Deprescribing

February 2019

Emerging cases in the ER: Managing Cannabinoid Hyperemesis Syndrome (CHS)

January 2019

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthoplasty (EPCAT2)

February 2018

Can DOACs be used to treat cancer-associated VTEs? A look at edoxaban.

March 2018

Understanding the why and how of obesity dosing for antibiotics: a narrative review of literature from 1966 to 2017

April 2018

Deprescribing opportunities in acute care – guidance from Choosing Wisely Canada. Part 1: Stool softeners, PPIs, benzodiazepines/sedative-hypnotics and combination ACEI/ARB therapy

• Missed Opportunity to Deprescribe: Docusate for Constipation in Medical Inpatients.
• Proton Pump Inhibitor (PPI) Deprescribing Algorithm
• Benzodiazepine & Z-Drug (BZRA) Deprescribing Algorithm
• Missed Opportunities for Deprescription: A Teachable Moment.

May 2018

Deprescribing opportunities in acute care – guidance from Choosing Wisely Canada. Part 2: Statins, opioids, antipsychotics and antibiotics for asymptomatic bacteriuria.

• Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.
• Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.
• Antipsychotic (AP) Deprescribing Algorithm
• An Implementation Guide to Reducing Overtreatment of Asymptomatic Bacteriuria.

June 2018

Improving the pharmacist handover process in the hospital: the I-HAPPY tool

July 2018

The revolving door of COPD exacerbations – how can we better optimize therapy before discharging the patient?

August 2018

Diluent shortages in the wake of Hurricane Maria: What can they teach us about the way we practice medicine?

• Anticipated shortage of 250mL and 500mL intravenous solutions manufactured by Baxter Corporation.
• Small-Volume Parenteral Solutions Shortages
• The Shortage of Normal Saline in the Wake of Hurricane Maria.
• I.V. push administration of medications reconstituted with 0.9% sodium chloride injection.
• Facing the Shortage of IV Fluids - A Hospital-Based Oral Rehydration Strategy.

September 2018

Are we ready for our next overdose patient? A discussion of recommended antidotes to be stocked in hospitals and national initiatives under development.

• Antidotes and Related Agents: Recognition of Need, Availability, and Effective Use
• Guidelines for Stocking Emergency Antidotes
• Expert Consensus Guidelines for Stocking of Antidotes in Hospitals That Provide Emergency Care.
• Path to the Canadian Antidote Registry

October 2018

Marijuana legalization on October 17: Reviewing medical marijuana therapy in acute care and considerations for unique inpatient populations.

• Compendium of Pharmaceuticals and Specialties (CPS 2019)
• Medical Cannabis Q&A
• Cannabinoids: Overview
• Should Medical Cannabis Administered by Inhalation Be Allowed for Hospitalized Patients?

November 2018

Who is at risk of oversedation in the hospital? Taking a closer look at the FROSH factors.

November 2017

Point counterpoint: Should digoxin continue to be used for atrial fibrillation?

October 2017

Managing diabetic emergencies – ketoacidosis (DKA), hyperglycemic hyperosmolar state (HHS) and hypoglycemia. Are we using evidence-based approaches?

September 2017

Medical marijuana – what is the evidence?
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

August 2017

Idarucizumab for dabigatran reversal(REVERSE-AD trial) Part 2 – Full cohort analysis

July 2017

Tackling one piece of the opioid crisis: Opioid initiation in the ER
Opioid-Prescribing Patterns of Emergency Physicians and Risk of Long-Term Use.

June 2017

Can PPI and H2 blocker stewardship reduce the risk of clostridium difficile infections?
Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.
Impact of a pharmacist-driven protocol to decrease proton pump inhibitor use in non-intensive care hospitalized adults.

May 2017

Are we underdosing VTE prophylaxis in our obese patients?
Chemical prophylaxis to prevent venous thromboembolism in morbid obesity: literature review and dosing recommendations.

April 2017

Teachable moments:
1) How to clarify a penicillin allergy
2) how to help patients sleep better in the hospital

March 2017

Incretin-based antihyperglycemics and acute pancreatitis: is there a link?
Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.

February 2017

Med Safety Blast – Health Product InfoWatch November and December 2016 issues

January 2017

Use of potentially inappropriate medications in alternate level of care (ALC) inpatients and a practical review of Beers Criteria
Application of the Beers Criteria to Alternate Level of Care Patients in Hospital Inpatient Units

November 2016

Using DOACs in morbid obesity – should we be worried?
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.
NOACS/DOACS: Coagulation Tests

October 2016

Triple antithrombotic therapy – are we doing it right?
Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention.

September 2016

Improving inhaler technique for hospitalized patients with COPD
Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease.

August 2016

Opioid discussions Part 2: Naloxone kits and Ontario Drug Benefit’s delisting of certain long-acting opioids
Dispensing or Selling Naloxone: Guidance
Reminder regarding Delisting of High-Strength Long-Acting Opiods under the ODB Program

July 2016

Opioid discussions Part 1: Preventing opioid overdoses in acute care
Retrospective analysis of opioid medication incidents requiring administration of naloxone.

June 2016

Idarucizumab for dabigatran reversal (REVERSE-AD trial) Part 1: Preliminary results

May 2016

Considerations for intravenous to oral antibiotic stepdown
Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

April 2016

Crediblemeds.org and assessing QT prolonging risk of drugs in context of clinical scenarios
Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.

March 2016

Subsequent entry biologics and implications on the hospital formulary
New Advances in Immunology: SEBs in Rheumatology, Dermatology, and Gastroenterology

Febraury 2016

Toujeo vs. Lantus in glycemic control and weight gain
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes.